Compare Crispr Therapeutics AG (CRSP) vs 3M Company (MMM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs 3M Company — how do they compare? Crispr Therapeutics AG trades at $54.31 (market cap $5.23B), while 3M Company trades at $183.92 (market cap $94.44B). The key difference: 3M Company is far larger — about 18.1× Crispr Therapeutics AG's market cap, and 3M Company pays a 1.7% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | MMM | |
|---|---|---|
Market Cap | $5.23B | $94.44B |
Sector | Health | Industrials |
52-Week High | $76.78 | $183.13 |
52-Week Low | $44.34 | $141.10 |
Enterprise Value | $3.65B | $103.67B |
Dividend Yield | — | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MMM trades at $182.04, showing modest daily weakness but maintaining a bullish technical trend with strong support near $181. Recent Q2 2026 earnings beat expectations with EPS of $2.40, driven by 5.4% organic growth and margin expansion, leading to raised full-year guidance. The stock's valuation remains elevated with a P/E of 32.53, while analyst sentiment is mixed with a near-even split between buy and hold ratings.
The outlook is cautiously optimistic, supported by operational improvements and innovation in high-growth verticals like Safety & Industrial. Key risks include litigation liabilities and macroeconomic pressures. Upside potential exists if execution continues to surpass expectations, but current prices may already reflect near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About 3M Company
3M Company conducts operations in electronics, telecommunications, industrial, consumer and office, health care, safety, and other markets. The Company businesses share technologies, manufacturing operations, marketing channels, and other resources. 3M serves customers worldwide.
Read more on MMM →
